Guidelines prostate brachytherapyTumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy
Section snippets
ICRU definitions [35]
Gross tumour volume (GTV). The gross tumour volume corresponds to the gross palpable, visible or clinically demonstrable location and extent of the malignant growth.
Given the TNM definition for prostate cancer, GTV can only be defined for tumour stages larger than T1c. For these tumour stages (>T1c), the GTV definition can be useful, certainly in cases where the tumour area can be identified, not only by digital rectal examination, but also by radiological examinations including transrectal
Conclusions
These recommendations should be considered in conjunction with the ESTRO/EAU/EORTC recommendations on permanent seed implantation for localised prostate cancer which were published in 2000. This guidance was, as noted in the paper, intended for those embarking on brachytherapy to identify the factors related to successful outcome but did not focus on target (prostate gland) or organ at risk (prostatic urethra, rectum) contouring, target definition, dosimetric parameters regarding target
References (87)
- et al.
Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry
Radiother Oncol
(2002) - et al.
Prostate seed implant quality assessment using MR and CT image fusion
Int J Radiat Oncol Biol Phys
(1999) - et al.
ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer
Radiother Oncol
(2000) Imaging for prostate cancer
Clin Oncolo (R Coll Radiol)
(2005)- et al.
Prostate cancer brachytherapy: Is real-time ultrasound-based dosimetry predictive of subsequent CT-based dose distribution calculation? A study of 450 patients by the Institut Curie/Hospital Cochin (Paris) Group
Int J Radiat Oncol Biol Phys
(2004) - et al.
Iodin 125 seed migration after prostate brachytherapy: a study of 170 patients
Cancer Radiother
(2004) - et al.
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications
J Urol
(1997) - et al.
Optimizing target coverage by dosimetric feedback during prostate brachytherapy
Int J Radiat Oncol Biol Phys
(2000) - et al.
MRI-CT fusion to assess postbrachytherapy prostate volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy
Brachytherapy
(2004) - et al.
Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy
Brachytherapy
(2002)
Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk
Brachytherapy
The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer
Int J Radiat Oncol Biol Phys
Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging
Int J Radiat Oncol Biol Phys
Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: Extraprostatic seed placement correlates with migration
Int J Radiat Oncol Biol Phys
Ultrasonography and fluoroscopic fusion for prostate brachytherapy dosimetry
Int J Radiat Oncol Biol Phys
Recommendations from Gynaecological (GYN GEC-ESTRIO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GRV and CTV
Radiother Oncol
Cell kinetic measurements in prostate cancer
Int J Radiat Oncol Biol Phys
Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants
Brachytherapy
Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants
Radiother Oncol
GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer
Radiother Oncol
Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator
Brachytherapy
Postimplant analysis of transperineal intestitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution
Int J Radiat Oncol Biol Phys
Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy
Int J Radiat Oncol Biol Phys
Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes
Radiother Oncol
Comparison of MRI pulse sequences in defining prostate volume after permanent implantation
Int J Radiat Oncol Biol Phys
Seed fixicity in the prostate/periprostatic region following brachytherapy
Int J Radiat Oncol Biol Phys
Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland
J Urol
Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging
Int J Radiat Oncol Biol Phys
The American Brachytherapy Society recommendations for permanent prostate brachytherapy post-implant dosimetric analysis
Int J Radiat Oncol Biol Phys
American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer
Int J Radiat Oncol Biol Phys
Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants
Int J Radiat Oncol Biol Phys
Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate
J Urol
Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy
J Urol
Standardization of prostate brachytherapy treatment plans
Int J Radiat Oncol Biol Phys
Prostate specific antigen in the staging of localised prostate cancer: influence of tumour differentiation, tumour volume and benign hyperplasia
J Urol
Morphometric measurements of tumor volume and per cent of gland involvement as predictor of pathological stage in clinical stage B prostate cancer
J Urol
MR and CT image fusion for postimplant analysis in permanent prostate seed implants
Int J Radiat Oncol Biol Phys
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image based treatment planning in cervix cancer brachytherapy – 3D dose volume parameters and aspects of 3D image-based anatomy, radiations physics, radiobiology
Radiother Oncol
Towards a dynamic real-time intraoperative permanent prostate brachytherapy methodology
Brachytherapy
A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy
Int J Radiat Oncol Biol Phys
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation
Radiother Oncol
The design and testing of a solid phantom for the verification of a commercial 3D seed reconstruction algorithm
Radiother Oncol
Seed loss in interstitial radiotherapy of prostatic carcinoma with 125I
Int J Radiat Oncol Biol Phys
Cited by (243)
The role of ESTRO guidelines in achieving consistency and quality in clinical radiation oncology practice
2023, Radiotherapy and OncologyGEC-ESTRO ACROP prostate brachytherapy guidelines
2022, Radiotherapy and OncologyBest practice in brachytherapy
2022, Cancer/RadiotherapieCitation Excerpt :Brachytherapy allows a heterogeneous dose distribution into the CTV according to increase the dose in the tumour index or specific area at high risk of local recurrence. The Groupe européen de curiethérapie of the European Society for Therapeutic Radiology and Oncology (Gec-ESTRO) have published recommendations for target volume definition and dose levels to consider according to the tumour location [7–12]. Organs at risk are healthy tissues located around or inside the CTV whose radiosensitivity can affect dose prescription or planning.
Prostate cancer brachytherapy: SFRO guidelines 2021
2022, Cancer/RadiotherapieCitation Excerpt :To facilitate registration, it is useful to first demarcate the prostate volumes in the two series of images and then fuse the images of the two structures. Clinical target volume (CTV) corresponds to the entire prostate gland with a possible 3-mm expansion excluding the rectum and neck of the bladder [5,71]. The planning target volume (PTV) corresponds to the CTV [71].